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Abstract
Background: Fibromyalgia (FM) is a chronic pain syndrome with unknown etiology and a wide spectrum of symptoms such
as allodynia, debilitating fatigue, joint stiffness and migraine. Recent studies have shown some evidences demonstrating
that oxidative stress is associated to clinical symptoms in FM of fibromyalgia. We examined oxidative stress and
bioenergetic status in blood mononuclear cells (BMCs) and its association to headache symptoms in FM patients. The effects
of oral coenzyme Q10 (CoQ10) supplementation on biochemical markers and clinical improvement were also evaluated.
Methods: We studied 20 FM patients and 15 healthy controls. Clinical parameters were evaluated using the Fibromyalgia
Impact Questionnaire (FIQ), visual analogues scales (VAS), and the Headache Impact Test (HIT-6). Oxidative stress was
determined by measuring CoQ10, catalase and lipid peroxidation (LPO) levels in BMCs. Bioenergetic status was assessed by
measuring ATP levels in BMCs.
Results: We found decreased CoQ10, catalase and ATP levels in BMCs from FM patients as compared to normal control
(P,0.05 and P,0.001, respectively) We also found increased level of LPO in BMCs from FM patients as compared to normal
control (P,0.001). Significant negative correlations between CoQ10 or catalase levels in BMCs and headache parameters
were observed (r =20.59, P,0.05; r =20.68, P,0.05, respectively). Furthermore, LPO levels showed a significant positive
correlation with HIT-6 (r = 0.33, P,0.05). Oral CoQ10 supplementation restored biochemical parameters and induced a
significant improvement in clinical and headache symptoms (P,0.001).
Discussion: The results of this study suggest a role for mitochondrial dysfunction and oxidative stress in the headache
symptoms associated with FM. CoQ10 supplementation should be examined in a larger placebo controlled trial as a
possible treatment in FM.
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Introduction
Fibromyalgia (FM) is a common chronic pain syndrome with an
unknown etiology, which has been associated with a wide
spectrum of symptoms such as allodynia, debilitating fatigue, joint
stiffness and depression. FM is diagnosed according to the
classification criteria established by the American College of
Rheumatology (ACR) [1]. Despite being a common disorder that
affects at least 5 million individuals in the United States [2], its
pathogenic mechanism remains elusive. In addition to the
described symptoms, a high prevalence of FM has been found
among patients with transformed migraine and headaches [3,4].
Common genetic basis, synergetically working with other factors
(emotional, personality features, stressful events and medication
overuse) should cause a chronic antinociceptive system alteration
and therefore a progressive increase (hyperalgesia) and diffusion
(panalgesia) of pain. It has been hypothesized that episodic
migraine, chronic daily headaches and FM may actually be a
continuum of the same disorder [5].
Recently, oxidative stress has been proposed as a relevant event
in the pathogenesis of FM and headaches [6,7]. Previously, our
group has detected decreased coenzyme Q10 (CoQ10) levels and
increased mitochondrial reactive oxygen species (ROS) production
in blood mononuclear cells (BMCs) from FM patients [8].
Furthermore, oxidative stress showed a significant correlation
with clinical symptoms in FM [6].
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CoQ10 levels and mitochondrial dysfunction have also been
implicated in the pathophysiology of migraine, and it has been
reported that oral CoQ10 supplementation improved clinical
symptoms [9].
The aim of this paper was first to establish a possible correlation
between oxidative stress parameters and severity of headaches in
FM, and secondly to study the effects of oral CoQ10 supplemen-
tation on the improvement in headache symptoms.
Patients and Methods
Ethics Statement
Written informed consent and the approval of the ethical
committee of University Pablo de Olavide and Universitary
Hospital Virgen Macarena from Seville were obtained, according
to the principles of the Declaration of Helsinki.
Patients
All samples were obtained after informed consent from patients
and the approval of the local ethical committee was obtained
according to the principles of the Declaration of Helsinki. The
study consisted of 20 women diagnosed with FM and 15 healthy
women. The inclusion criteria was fibromyalgia that had been
diagnosed for the previous 2 to 3 years, based on the current ACR
diagnostic criteria 1. Exclusion criteria were acute infectious
diseases in the previous 3 weeks; past or present neurological,
psychiatric, metabolic, autoimmune, allergy-related, dermal or
chronic inflammatory disease; undesired habits (e.g., smoking,
alcohol, etc.); oral diseases (e.g., periodontitis); medical conditions
that required glucocorticoid treatment, use of analgesics, statin or
antidepressant drugs; past or current substance abuse or
dependence and pregnancy or current breastfeeding. Healthy
controls had no signs or symptoms of FM and were free of any
medication for at least 3 weeks before the study began. All patients
and controls had taken no drugs or vitamin/nutritional supple-
ment during the 3 week period prior to the collection of the blood
samples. Before the study, the patients reported using paracetamol
on demand. Clinical data was obtained from physical examina-
tion, and evaluated using the Fibromyalgia Impact Questionnaire
(FIQ) including visual analogues scales about general and diffuse
pain typical of FM (VAS), and Headache Impact Test (HIT-6).
Blood mononuclear cells
Heparinized blood samples were collected after 12-hours fasting
from patients and healthy age and sex-matched control subjects.
BMCs were purified from heparinized blood by isopycnic
centrifugation using Histopaque-1119 and Histopaque-1077
(Sigma Chemical Co., St. Louis, MO, USA).
Measurement of CoQ10 levels
CoQ10 content in BMCs were analyzed by HPLC (Beckman
Coulter, Brea, CA, USA; 166-126 HPLC) with ultraviolet
detection (275 nm), according to the method described above [8].
Lipid peroxidation
Lipid peroxidation in cells was determined by analyzing the
accumulation of lipoperoxides using a commercial kit from
Cayman Chemical (Ann Arbor, Michigan, USA). TBARS are
expressed in terms of malondialdehyde (MDA) levels. In these
assays, an MDA standard is used to construct a standard curve
against which unknown samples can be plotted.
Catalase determination
A spectrophotometric method described by Beer and Sizer
(1952) [10] was used for measuring the breakdown of hydrogen
peroxide by catalase. Briefly, activity was determined by using
35 mg of cell lysate, prepared in a lysis buffer composed of 0.9%
NaCl, 20 mM Tris.ClH, pH = 7.6, 0.1% triton X-100, 1 mM
phenylmethylsulfonylfluoride and 0.01% leupeptine with gentle
shaking, in a kinetic spectrophotometric assay that measures a
decrease in the absorbance of hydrogen peroxide.
ATP levels
ATP levels were determined by a bioluminescence assay using
an ATP determination kit from Invitrogen-Molecular Probes
(Eugene, OR, USA) according to the instructions of the
manufacturer.
Oral CoQ10 supplementation
Ten volunteer patients were supplemented with CoQ10
(Pharma Nord, Vejle, Denmark) with soft gel capsules for 3
months (300 mg/day CoQ10 divided in three doses). After 3
months of treatment, heparinized blood samples were collected
after 12-hours fasting and 24 hours after the last dose, and clinical
symptoms were evaluated. The CoQ10 formulation consisted of
soft gelatin capsules containing 100 mg of ubiquinone emulsified
with diglyceryl monooleate, beeswax, soy lecithin and canola oil.
Statistical Analysis
All results are expressed as mean 6 SD unless stated otherwise.
The unpaired Student’s t test was used to evaluate the significance
of differences between groups. Statistical analyses included
Pearson’s correlations between CoQ10, catalase, and MDA levels
in compared with Hit-6 score. P values less than 0.05 were
considered significant. Data were analysed using the SPSS/PC
statistical software package (SPSS for Windows, 19, 2010, SPSS
Inc. Chicago, IL, USA).
Results
Oxidative stress in FM
The mean age of patients was 46.665 years for the FM group
and 44.964 years for the control group. The mean duration of
symptoms in the FM group was 10.164.2 years. The mean tender
point score in the FM group was 14.861.7 points. According to
International Headache Society (IHS) criteria, the headache was
tension-type headache. The mean of frequency of headache was
361 per week. The duration of headache episodes was
1062 hours. The patients did not describe any symptoms such
as nausea, photophobia, or aura.
The most prominent features of these FM patients were pain
and stiffness. They were sedentary people and routine laboratory
tests yielded normal results for glucose, urea, uric acid, total
protein, creatinine, aspartate aminotransferase, alanine amino-
transferase, cholesterol and triglycerides (data not shown). The
number and subgroup distribution of BMCs (monocytes and
limphocytes) in FM patients were in the normal range (data not
shown).
To evaluate the antioxidant system in FM patients, CoQ10 and
catalase levels in BMCs were examined and compared to control
subjects. Both, CoQ10 and catalase levels were significantly
reduced in FM patients, 64.3% and 40% respectively (Figure 1A
and 1B). We also determined LPO levels in BMCs from FM
patients as a marker of oxidative stress-induced membrane
damage by ROS. FM patients showed higher LPO levels in
BMCs, 610% with respect to control subjects (Figure 1C).
Oxidative Stress and Headache in Fibromyalgia
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To determine whether the observed CoQ10 deficiency had an
effect on cellular bioenergetics, we measured intracellular ATP
levels in BMCs from control and FM patients. ATP levels were
reduced to 70% of the control value in BMCs from FM patients
(Figure 1D).
Headache correlates with oxidative stress in FM patients
All FM patients showed high HIT-6 scores compared with
control subjects (Table 1). To examine whether headache
symptoms were associated to increased oxidative stress, Pearson’s
correlation coefficients (r) were performed between CoQ10,
catalase or LPO levels and HIT-6 scores. Figure 2 shows a
significant negative correlation between CoQ10 and catalase levels
and HIT-6 (r =20.59, P,0.05; r =20.68, P,0.05, respectively).
Furthermore, LPO levels showed a significant positive correlation
with HIT-6 (r = 0.33, P,0.05). No correlation of ATP levels and
HIT-6 scores was found (data not shown).
Influence of oral Coenzyme Q10 supplementation
Table 2 shows levels of biochemical markers in control subjects
and before and after treatment with CoQ10. In FM patients
treated with CoQ10, all levels of oxidative stress markers were
similar to those measured in control subjects. CoQ10 supplemen-
tation significantly increased levels of CoQ10, ATP and catalase
but all levels were lower than those seen in controls. In contrast,
MDA in BMCs declined and fell to levels similar to those seen in
controls. These biochemical marker changes were associated with
improvement of clinical measured by tender points, FIQ VAS and
HIT-6 scores.
We observed a significant increase of CoQ10 levels after
treatment (135.666.3 pretreatment and 221.6611.3 postreat-
ment, P,0.001) (respect to control, 224.4612.3;P,0.001), ATP
levels (61.364.9 pretreatment and 191.166.7 postreatment,
P,0.001) (respect to control, 202.8622.1;P,0.001) and catalase
levels (35.6610.1 pretreatment and 85.2615.3 postreatment,
P,0.001) (respect to control, 96.5614.8; P,0.001) in BMCs, a
reduction of LPO levels (30.365.9 pretreatment and 5.161.6
postreatment, P,0.001) (respect to control, 661; P,0.001) and a
marked improvement of clinical symptoms (FIQ: P,0.01; VAS:
P,0.01; HIT-6: P,0.05) (Table 2). No biochemical alterations
were detected after CoQ10 treatment: glucose 82,3610,16 mg/dL
(normal range: 76–110), urea 29,765,31 mg/dL (normal range:
10–45), uric acid 5,161,41 mg/dL (normal range: 2.5–7.5), total
protein 7,261,01 g/dL (normal range: 6.6–8.7), creatinine
0,960,13 mg/dL (normal range: 0.5–1.1), aspartate aminotrans-
ferase 24,365,17 mU/mL (normal range: 10–40), alanine ami-
Figure 1. Coenzyme Q10 levels, catalase levels and lipid peroxidation (MDA levels) in blood mononuclear cells (BMCs) from
fibromyalgia (FM) patients and healthy control individuals. (A) CoQ10 levels were measured by HPLC, as described in Materials and Methods.
(B) Catalase was analyzed in BMCs as described in Materials and Methods. (C) LPO was measured as described in Material and Methods. (D) ATP levels
were analyzed in BMCs as described in Materials and Methods. Data represent the mean 6 SD of three separate experiments.
doi:10.1371/journal.pone.0035677.g001
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notransferase 21,268,11 mU/mL (normal rage: 10–40), total
cholesterol 20569,01 mg/dL (normal range: ,220), and triglyc-
erides 168631,13 mg/dL (normal range: 150–200).
Discussion
In the present study we have confirmed a significant increase of
oxidative stress in FM patients, showing a marked decrease of
CoQ10, ATP and catalase levels and a significant increase of LPO
levels in BMCs compared to control subjects.
Coenzyme Q10 (CoQ10) is present in every membrane of all
cells in the body. CoQ10 transfers electrons from complexes I and
II to complex III in the mitochondrial respiratory chain and fulfills
a critical role in mitochondrial ATP production, playing a crucial
role in cellular metabolism; regulating mitochondrial uncoupling
proteins, the mitochondrial permeability transition pore, b-
oxidation of fatty acids, nucleotide metabolism and production
of reactive oxygen species (ROS) [11,12]. It has been widely
demonstrated that CoQ10 is essential for respiratory chain efficacy,
and as antioxidant [13,14,15]. CoQ10 deficiency has been
associated with several diseases with the typical symptoms found
in FM patients [16,17]. Interestingly, CoQ10 deficiency has been
detected in depression and chronic fatigue [18,19], two typical
symptoms found in FM patients. Furthermore, both symptoms
were markedly improved after CoQ10 supplementation. Our
results are in agreement with those of previous reports which have
shown that CoQ deficiency is associated with decreased ATP
levels and increased oxidative stress [20,21]. Oxidative stress and,
in particular, LPO levels have been implicated in the severity of
the clinical symptoms in FM and it has been suggested that
antioxidant therapy could be beneficial in FM [6]. On the other
hand, the oxidant-antioxidant balance disorders underlie a
number of acute and chronic diseases of the central nervous
system (CNS) [22]. Clinical conditions affecting the nervous
system range from mild cognitive perturbations such as headache
or migraine, to life-threatening acute courses such as meningitis,
and to chronic neurodegenerative diseases such as multiple
sclerosis. One common feature in clinical dysfunctions within the
nervous system is redox regulation, with an imbalance in oxidative
stress versus antioxidants being characteristic of pathological
conditions. It is believed that oxidative stress and LPO play a role
in the pathogenesis of migraine by regulating cerebral blood flow
and energy metabolism and may constitute a trigger threshold for
migraine attacks [23,24]. Moreover, emerging data suggest that
LPO may underlie the neuronal alterations and neurotoxicity
observed in numerous neuropathological conditions. Direct
application of LPO, either in vivo or in vitro, has been shown to
be cytotoxic and to mimic neuronal alterations observed in
neuropathological conditions. In addition, prevention of LPO has
been demonstrated to be neuroprotective in a variety of
neuropathological paradigms [25]. It is known that LPO, as a
consequence of oxidative stress, indirectly reflects intracellular
ROS generation, and ROS are known to be implicated in the
etiology of pain, one of the most prominent symptoms in FM, by
inducing peripheral and central hyperalgesia [26].
Our results show an important significant correlation between
LPO levels and headache symptoms in FM patients. Antioxidants
(CoQ10 and catalase) levels also showed a significant negative
correlation with headache symptoms. CoQ10 has two important
functions in cells: first, CoQ10 is a mitochondrial cofactor with the
potential to boost mitochondrial function, and second, CoQ10 is a
powerful free radical scavenger that can mitigate lipid peroxida-
tion and DNA damage caused by oxidative stress [27]. In our
study, we have observed a marked improvement in headache
Figure 2. Correlation of CoQ10, catalase or lipid peroxidation
levels in BMCs from FM patients and HIT-6 levels.
doi:10.1371/journal.pone.0035677.g002
Table 1. Characteristic finding of FM patients and control
groups.
Patients (n =20) Control (n = 15)
Age (yr) 46.6 65 44.9 64
Tender points 14.8 61.7 ---
Duration of disease
(years)
10.1 64.2 ---
FIQ Total score, range 0–
100
60.2 65.6* 7.1 61.4
VAS, range 0–10 6.9 61.3* 0.8 60.3
HIT-6, range 36–78 61.8 61.3* 36.1 61.1
VAS: Visual Analogue Scale; FIQ: Fibromyalgia Impact Questionnaire; HIT-6:
Headache Impact Test. Values are means 6SD,
*P,0.001.
doi:10.1371/journal.pone.0035677.t001
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symptoms and a significant recovery in oxidative stress markers
after CoQ10 supplementation, suggesting that CoQ10 may be
involved in the pathophysiology of headache symptoms in FM.
Mitochondria have long been postulated to be involved in the
etiology of migraines, although a direct link has not been identified
[28]. In addition, the inflammatory component of migraines may
produce oxygen free radicals, consuming CoQ10 and inducing
CoQ10 deficiency [29].
Clinical studies have generated evidence that FM is associated
with immune dysregulation of circulatory levels of pro-inflamma-
tory cytokines, affecting neural function of pain-related neuro-
transmitters [30]. Cytokines, depending on their concentration,
induce symptoms, such as fatigue, fever, sleep, pain, and myalgia
[31], all of which develop in FM patients. Alterations in pro-
inflammatory cytokine levels have been observed in the serum and
skin biopsies of FM patients [32,33]. Interestingly, several studies
have also suggested that inflammatory processes are involved in
the physiopathology of migraine [34,35]. The inflammatory and
pain component of FM and migraine is behind the rationale of
using nonsteroidal anti-inflammatory drugs (NSAIDs) for the
treatment of both symptoms. However, while the use of NSAIDs
for fibromyalgia is a fairly common practice, little objective
evidence is available upon which to assess the efficacy of these
agents [36]. There are multiple mechanisms of action upon which
the NSAIDs act. There have been conflicting reports as to whether
NSAIDs such as acetylsalicylic acid are effective in protecting
neurons against neurotoxicity. Acetaminophen has been shown to
rescue neuronal cells from mitochondrial redox impairment,
lipoperoxidative products and MDA generation [37]. Further-
more, acetaminophen also reduced the cytoplasmic accumulation
of peroxides. Acetylsalicylic acid and acetaminophen inhibit lipid
peroxidation and cell damage, in vivo, in the rat hippocampus
[38]. The results obtained when NSAIDs are combined with
benzodiazepines have also been inconsistent [39]. However,
NSAIDs can be helpful in reducing pain flares induced by
excessive physical activity, tendinitis or bursitis, although they
should only be used on an as needed basis in order to avoid side
effects [40].
In addition of pro-inflammatory cytokines, CoQ10 deficiency is
also involved in inflammation. A significant negative correlation
has been observed between CoQ10 and pro-inflammatory markers
in septic shock patients [41], and expression profiling revealed that
CoQ10 influences the expression of inflammatory genes suggested
that CoQ10 exerts anti-inflammatory properties. In another study,
administration of CoQ10 significantly attenuated the increase of
oxidative and nitrative stress markers and inflammatory markers
in an animal model of metabolic syndrome [42].
In summary, headache symptoms in FM could be a conse-
quence of oxidative stress and both may share common
pathophysiologic basis. Furthermore, CoQ10 treatment showed a
remarkable improvement in clinical symptoms and headache in
FM. Detection of CoQ10 deficiency and subsequent CoQ10
supplementation may result in clinical improvement in FM.
Further analysis involving doubled-blind placebo-controlled clin-
ical trials will be required to confirm this observation.
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